From: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
References | [90] | [100] | [106] | [89] | [121] | [160] | [88] | [129] | [135] | [135] | [145] | [152] | [91] | [159] | [160] | [161] | [161] |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sponsor | Beijing Institute of Microbiology and Epidemiology | Wuhan Institute of Virology | University of Pennsylvania | VIB-UGent Center for Medical Biotechnology | Infectious Disease Research Institute | Tübingen | Moderna, Inc. | Fudan University | Georgia Institute of Technology and Emory University | Georgia Institute of Technology and Emory University | Dongtai People’s Hospital | Massachusetts Institute of Technology | BioNTech | niversity of North Carolina at Chapel Hill Chapel Hill | Tübingen | Moderna, Inc. | Moderna, Inc. |
Dosege | 0.2 and 1 mg/kg | 5 × 105 IU | 1 and 1.4 mg/kg | 5 µg | 40 µg | 40 µg | 0.1, 0.3 and 0.6 mg/kg | 2.5 mg/kg | 20 and 100 µg | 100 µg | 0.2, 0.6 and 2 mg/kg | 8 mg/kg | 5 µg | 1 mg/kg | 40 µg | 1 mg/kg | 1 mg/kg |
Route | I.V. | I.T. | I.V. | I.T. | I.M. | I.M. | I.V. | I.V. | I.T. | I.T. | I.V. | I.V. | I.V. | I.V. | I.V. | I.V. | I.V. |
Main components of vector | DSPC, cholesterol and PEG-lipid | Â | PEG-lipid, cholesterol, ionizable cationic lipid | DOTAP and cholesterol | Squalene, glyceryl trimyristate, DOTAP | Phosphatidylcholine, cholesterol, PEG-lipid | DSPC, cholesterol and PEG-lipid | DSPC, cholesterol, DMG-PEG2000 | Â | Â | Phosphatidylcholine, PEGylated lipid cholesterol | cKK-E12 | TransIT-mRNA Transfection kit | MC3 LNPs | Phosphatidylcholine, cholesterol, PEG-lipid | Undisclosed | Undisclosed |
Indication | RBD | RBD | HIV-1 gp120 | FcgRIV & M2e | ZIKV | Rabies | CHIKV | HBsAg | RSV | RSV | PD1 | HER2 | TAAs | CCL2 & CCL5 | Botulinum toxin | O5-antigen | Psl |
Diseases | SARS-CoV-2 | SARS-CoV-2 | HIV-1 | Influenza A Virus | Zika Virus | Rabies | Chikungunya virus | Hepatitis B Virus | Respiratory syncytial virus | Respiratory syncytial virus | Oncology | Oncology | Oncology | Oncology | Toxins | STm | PA |
Format | IgG | IgG | IgG | Bispecific | IgG | IgG | IgG | scFv, scFv-Fc, IgG | IgG | VHH | IgG | IgG | Bispecific | Bispecific | VNA | IgA2 | IgA1 |
Antibodies | HB27 | CB6 | VRC01 | RiboBiFE | ZIKV-117 | S057(CR57) | mRNA-1944 | G12 | Palivizumab | RSV aVHH | Pembrolizumab | Trastuzumab | RiboMAbs | BisCCL2/5i | BoNT/A | Sal4 | CAM003 |